Bringing Clinical Trials to Life

Dermatology

Together, Cu-Tech and Synteract create the leading dermatology CRO, with global capabilities and unparalleled access to sites and patients. Our focus on novel and required dermatology drugs provides dedicated research services unmatched in the market.
More...

Oncology

Like our clients, we are committed to the quest to cure cancer. But cancer is not just a single disease. It takes deep trial knowledge to know how to address its many forms. Learn how Synteract has stayed ahead of the trends leading towards new treatments…
More...

Neuro Degenerative

Neuro degenerative disorders are some of the most confounding and complex to affect people. Our specialized experience in these trials aids you in developing treatments that improve functioning and help the lives of both patients and caregivers…
More...

Rare & Orphan Diseases

Rare and orphan diseases have unique characteristics, not the least of which is finding the right population for your trials. We know the investigators and study sites that can help to address your recruitment goals, among other challenges…
More...

Pediatrics

Pediatric trials run the gamut of indications in drug development, but they all have primary things in common – working with children and their families requires specialized expertise and deep knowledge of regulatory requirements….
More...

7/19/2018 - 7/26/2018 : Alzheimer’s Association International Conference More...

7/11/2018: Synteract acquires Cu-Tech, a leading dermatology CRO More ...

5/31/2018: DIA 2018 Is On The Horizon! - Are you planning to attend DIA 2018 this year? We would love to see you there! Synteract will be exhibiting in Boston in booth #1104, June 24-28th.

Synteract Blog 

7/17/2018: What are the leading challenges for studies in neurodegenerative diseases?  Linda Rawlings, VP of Neurodegenerative Development,  answers this question and several others in the following Applied Clinical Trials blog post: "CROs Tackle Neurodegenerative Disease Studies" https://lnkd.in/gbpG2EC

Synteract on LinkedIn

7/13/2018: Our CCO Jack Shannon spoke with @melfass from @OutsourcPharma about our acquisition of Cu-Tech and our new… https://t.co/KCkFxHJJk3

Synteract Twitter Feed
x

Contact Synteract

Tell us how to stay in touch with you:

*Required